8
Journal of Chemistry
for new drugs,” Current Biotechnology, vol. 3, no. 4, pp. 1–10,
[23] A. Zarghi, R. Ghodsi, E. Azizi, B. Daraie, M. Hedayati, and
O. G. Dadrass, “Synthesis and biological evaluation of new 4-
carboxyl quinoline derivatives as cyclooxygenase-2 in-
hibitors,” Bioorganic and Medicinal Chemistry, vol. 17, no. 14,
pp. 5312–5317, 2009.
2014.
[6] P. B. de Carvalho and E. I. Ferreira, “Leishmaniasis phyto-
therapy. Nature’s leadership against an ancient disease,”
Fitoterapia, vol. 72, no. 6, pp. 599–618, 2001.
[7] H. W. Murray, J. D. Berman, C. R. Davies, and N. G. Saravia,
“Advances in leishmaniasis,” Ce Lancet, vol. 366, no. 9496,
pp. 1561–1577, 2005.
[8] J. V. Richard and K. A. Werbovetz, “New antileishmanial
candidates and lead compounds,” Current Opinion in
Chemical Biology, vol. 14, no. 4, pp. 447–455, 2010.
[9] D. Pathak, M. Yadav, N. Siddiqui, and S. Kushawah, “Anti-
leishmanial agents: an updated review,” Der Pharma Chemica,
vol. 3, no. 1, pp. 239–249, 2011.
[10] P. Desjeux and J. Alvar, “Leishmania/HIV co-infections:
epidemiology in Europe,” Annals of Tropical Medicine and
Parasitology, vol. 97, no. 1, pp. S3–S15, 2003.
[11] J. Alvar, P. Aparicio, A. Aseffa et al., “,e relationship between
leishmaniasis and AIDS: the second 10 years,” Clinical Mi-
crobiology Reviews, vol. 21, no. 2, pp. 334–359, 2008.
[12] F. Modabber, “Leishmaniasis vaccines: past, present and fu-
ture,” International Journal of Antimicrobial Agents, vol. 36,
no. 1, 2010.
[13] S. S. Soumya Neelagiri and I. Sravan Kumar, “Tools for
antileishmanial drug discovery and drug development,”
Current Research in Phamaceutical Science, vol. 11, no. 2,
pp. 22–28, 2010.
[14] B. Nare, J. Luba, L. W. Hardy, and S. Beverley, “New ap-
proaches to Leishmania chemotherapy: pteridine reductase 1
(PTR1) as a target and modulator of antifolate sensitivity,”
Parasitology, vol. 114, pp. S101–S110, 1997.
[15] M. Ouellette, J. Drummelsmith, and B. Papadopoulou,
“Leishmaniasis: drugs in the clinic, resistance and new de-
velopments,” Drug Resistance Updates, vol. 7, no. 4–5,
pp. 257–266, 2004.
[16] H. Wang, Z. Yan, J. Geng, S. Kunz, T. Seebeck, and H. Ke,
“Crystal structure of the Leishmania major phosphodiesterase
LmjPDEB1 and insight into the design of the parasite-
selective inhibitors,” Molecular Microbiology, vol. 66, no. 4,
pp. 1029–1038, 2007.
[17] S. L. Croft, K. Seifert, and V. Yardley, “Current scenario of
drug development for leishmaniasis,” Indian Journal of
Medical Research, vol. 123, no. 3, pp. 399–410, 2006.
[18] S. L. Croft and G. H. Coombs, “Leishmaniasis- current
chemotherapy and recent advances in the search for novel
drugs,” Trends in Parasitology, vol. 19, no. 11, pp. 502–508,
2003.
[19] P. J. Guerin, P. Olliaro, S. Sundar et al., “Visceral leish-
maniasis: current status of control, diagnosis, and treatment,
and a proposed research and development agenda,” Lancet
Infectious Diseases, vol. 2, no. 8, pp. 494–501, 2002.
[20] N. Singh, M. Kumar, and R. K. Singh, “Leishmaniasis: current
status of available drugs and new potential drug targets,”
Asian Pacific Journal of Tropical Medicine, vol. 5, no. 6,
pp. 485–497, 2012.
[21] A. M. L. Carmo, F. M. C. Silva, P. A. Machado et al., “Synthesis
of 4-aminoquinoline analogues and their platinum(II) com-
plexes as new antileishmanial and antitubercular agents,”
Biomedicine and Pharmacotherapy, vol. 65, no. 3, pp. 204–
209, 2011.
[22] A. Marella, O. P. Tanwar, R. Saha et al., “Quinoline: a versatile
heterocyclic,” Saudi Pharmaceutical Journal, vol. 21, no. 1,
pp. 1–12, 2013.
[24] M. A. Fakhfakh, A. Fournet, E. Prina et al., “Synthesis and
biological evaluation of substituted quinolines: potential
treatment of protozoal and retroviral co-infections,” Bio-
organic and Medicinal Chemistry, vol. 11, no. 23, pp. 5013–
5023, 2003.
[25] A. Fournet, M. E. Ferreira, A. Rojas De Arias et al., “In vivo
efficacy of oral and intralesional administration of 2-
substituted quinolines in experimental treatment of new
world cutaneous leishmaniasis caused by Leishmania ama-
zonensis,” Antimicrobial Agents and Chemotherapy, vol. 40,
no. 11, pp. 2447–2451, 1996.
[26] V. S. Gopinath, J. Pinjari, R. T. Dere et al., “Design, synthesis
and biological evaluation of 2-substituted quinolines as po-
tential antileishmanial agents,” European Journal of Medicinal
Chemistry, vol. 69, no. 2013, pp. 527–536, 2013.
[27] H. Nakayama, J. Desrivot, C. Bories et al., “In vitro and in vivo
antileishmanial efficacy of a new nitrilquinoline against
Leishmania donovani,” Biomedicine and Pharmacotherapy,
vol. 61, no. 2–3, pp. 186–188, 2007.
[28] S. B. Cammerer, C. Jimenez, S. Jones et al., “Quinuclidine
derivatives as potential antiparasitics,” Antimicrobial Agents
and Chemotherapy, vol. 51, no. 11, pp. 4049–4061, 2007.
¨
[29] L. Everson, P. Teixeira, D. S. Jr, E. Nunes, and R. Korting, “In
vitro antiprotozoal evaluation of zinc and copper complexes
based on sulfonamides containing 8-aminoquinoline li-
gands,” Letters in Drug Design and Discovery, vol. 7, no. 9,
pp. 679–685, 2010.
[30] L. E. da Silva, A. C. Joussef, L. K. Pacheco, D. G. da Silva,
M. Steindel, and R. A. Rebelo, “Synthesis and in vitro eval-
uation of leishmanicidal and trypanocidal activities of
N-quinolin-8-yl-arylsulfonamides,” Bioorganic and Medicinal
Chemistry, vol. 15, no. 24, pp. 7553–7560, 2007.
[31] G. Chakrabarti, A. Basu, P. P. Manna, S. B. Mahato,
N. B. Mandal, and S. Bandyopadhyay, “Indolylquinoline
derivatives are cytotoxic to Leishmania donovani promasti-
gotes and amastigotes in vitro and are effective in treating
murine visceral leishmaniasis,” Journal of Antimicrobial
Chemotherapy, vol. 43, pp. 359–366, 1999.
[32] P. Palit, P. Paira, A. Hazra et al., “Phase transfer catalyzed
synthesis of bis-quinolines: antileishmanial activity in ex-
perimental visceral leishmaniasis and in vitro antibacterial
evaluation,” European Journal of Medicinal Chemistry, vol. 44,
no. 2, pp. 845–853, 2009.
[33] L. Paloque, C. Hemmert, A. Valentin, and H. Gornitzka,
“Synthesis, characterization, and antileishmanial activities of
gold(I) complexes involving quinoline functionalized
N-heterocyclic carbenes,” European Journal of Medicinal
Chemistry, vol. 94, pp. 22–29, 2015.
[34] M. O. Faruk Khan, M. S. Levi, B. L. Tekwani, N. H. Wilson,
and R. F. Borne, “Synthesis of isoquinuclidine analogs of
chloroquine: antimalarial and antileishmanial activity,” Bio-
organic and Medicinal Chemistry, vol. 15, no. 11, pp. 3919–
3925, 2007.
[35] K. Lackovic, J. P. Parisot, N. Sleebs et al., “Inhibitors of
Leishmania GDP-mannose pyrophosphorylase identified by
high-throughput screening of small-molecule chemical li-
brary,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 5,
pp. 1712–1719, 2010.